Clients News • MC Services corporate website
5522
paged,page-template-default,page,page-id-5522,paged-57,page-paged-57,bridge-core-2.1.4,qode-listing-1.0.1,qode-social-login-1.0,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode-title-hidden,paspartu_enabled,qode_grid_1400,footer_responsive_adv,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-20.1,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-6.3.0,vc_responsive

CLIENT NEWS

 

 

  • Motif Bio plc: Motif BioSciences Enters into Amendment Agreement with Hercules Capital
    18 February 2019
    www.motifbio.com
  • InflaRx N.V.: Richard Brudnick to join InflaRx Board of Directors
    14 February 2019
    www.inflarx.com
  • BIO-Europe Spring® comes to Vienna for Europe’s most important springtime life science partnering event
    14 February 2019
    www.ebdgroup.knect365.com
  • Medigene AG: Medigene appoints Axel-Sven Malkomes as CFO/CBDO
    11 February 2019
    www.medigene.com
  • Adrenomed AG announces publication of Phase II trial design of Adrecizumab to treat septic shock
    07 February 2019
    www.andrenomed.com
  • InflaRx Announces Presentation of New Clinical Data with Lead Candidate IFX-1 in Hidradenitis Suppurativa
    06 February 2019
    www.inflarx.com
  • MagForce AG: Newly launched ’NanoTherm® Therapy School’ kicks off with successful first training session
    06 February 2019
    www.magforce.de
  • MorphoSys Announces Appointment of David Trexler as President and Member of the Board of Directors of MorphoSys US Inc.
    05 February 2019
    www.morphosys.com
  • Motif Bio plc: Exercise of Warrants
    05 February 2019
    www.motifbio.com
  • NOXXON Pharma: new data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer
    01 February 2019
    www.noxxon.com